Home › Compare › CRTDW vs ABBV
CRTDW yields 400000.00% · ABBV yields 3.06%● Live data
📍 CRTDW pulled ahead of the other in Year 1
Combined, CRTDW + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CRTDW + ABBV for your $10,000?
Creatd, Inc., a technology company, provides economic opportunities for creators in the United States. It operates in four segments: Creatd Labs, Creatd Partners, Creatd Ventures, and Creatd Studios. The company's flagship product is Vocal that delivers a digital publishing platform organized into niche-communities capable of hosting various rich media content. Its Vocal platform enhances the visibility of content and maximizes viewership; and provides advertisers access to target markets that closely match its interests. The company also offers Vocal for Brands, a content marketing that fosters relationships between brands and creators through its suite of agency services; Seller's Choice, performance marketing initiatives; and WHE Agency, an influencer marketing. In addition, it builds, develops, and scales e-commerce brands, such as Camp and Dune Glow Remedy. Further, the company's Creatd studios elevates creators to develop their content for television, film, prints, and podcasts. It serves businesses and consumers. The company was formerly known as Jerrick Media Holdings, Inc. and changed its name to Creatd Inc. in September 2020. Creatd, Inc. is headquartered in New York, New York.
Full CRTDW Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.